Get the latest news, insights, and market updates on BAX (Baxter International Inc.). Explore the news page 6 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
1 Stock Under $50 with Impressive Fundamentals and 2 We Question
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models. Jan 16, 2026 - $BAX
Does Baxter International (BAX) Now Look Fairly Priced After Multi‑Year Share Price Slide
If you are wondering whether Baxter International's current share price reflects its underlying worth, this article is designed to help you break that question down clearly. The stock most recently closed at US$20.15, with returns of 1.3% over the past week, 5.2% over the past month, 3.3% year to date, but a 32.7% decline over one year, 51.5% decline over three years, and 72.0% decline over five years. These share price moves sit against a backdrop of ongoing attention on Baxter... Jan 13, 2026 - $BAX
Why Baxter (BAX) Stock Is Trading Lower Today
Shares of healthcare company Baxter International (NYSE:BAX) fell 4.5% in the afternoon session after Barclays lowered its price target on the stock to $30 from $36, signaling a more cautious outlook on the company. Jan 12, 2026 - $BAX
Baxter to Present at J.P. Morgan 2026 Healthcare Conference
DEERFIELD, Ill., January 06, 2026--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026. Andrew Hider, Baxter’s president and chief executive officer, is scheduled to present at 2:15 p.m. Pacific Time. Jan 6, 2026 - $BAX
Assessing Baxter International (BAX) Valuation After Recent Share Price Momentum And Margin Concerns
Baxter International (BAX) has drawn fresh investor attention after recent trading, with the share price at $19.50 and mixed returns over the month and past 3 months prompting closer scrutiny of its fundamentals. See our latest analysis for Baxter International. The recent 1 day share price return of 2.04% and 1 month share price return of 5.18% sit against a 1 year total shareholder return decline of 33.07%. This indicates that short term momentum is improving, while longer term performance... Jan 5, 2026 - $BAX
Artisan Mid Cap Value Fund’s Views on Baxter International (BAX)
Artisan Partners, an investment management company, released its “Artisan Mid Cap Value Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the quarter, the fund’s Investor Class fund ARTQX returned 0.97%, Advisor Class fund APDQX posted a return of 0.98%, and Institutional Class fund APHQX returned 0.97%, compared to […] Jan 5, 2026 - $BAX
How Investors May Respond To Baxter (BAX) Retiring Near‑Term Debt And Advancing Connected Infusion Therapy
In December 2025, Baxter International Inc. completed the final settlement of its cash tender offers, retiring all of its 2.600% senior unsecured notes due 2026 and purchasing a substantial portion of its 1.915% senior unsecured notes due 2027 for up to US$600,000,000 in aggregate, including US$2,610,000 of 2026 notes bought at US$960.50 per US$1,000 of principal plus accrued interest. By reducing near-term debt obligations through these tender offers, Baxter has adjusted its balance sheet... Jan 4, 2026 - $BAX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple